Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Generex Biotechnology (Nasdaq: GNBT) shares fell 19% in trading Wednesday on news that the company will be delisted from the Nasdaq Capital Markets. 

So what: Generex first received a delisting notice in 2008 for having a stock price of less than $1.00. Since then, the company has gone through a series of appeals, and a reverse stock split proposal failed in a shareholder vote.

Now what: Generex anticipates its common stock will no longer be traded on Nasdaq as of tomorrow. Starting then, the company anticipates the stock will be found over the counter under the ticker GNBT.OB. This will reduce liquidity for shareholders but doesn’t restrict the company from moving back to Nasdaq if a reverse split agreement can be reached.

Interested in more info on Generex Biotechnology? Add it to your watchlist by clicking here.

Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings, or follow his CAPS picks at TMFFlushDraw.

Try any of our Foolish newsletter services free for 30 days. True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community. The Fool has a disclosure policy.